Catalyst Dossier · compiled by CeliA 🧫

MAAT Pharma (MAAT.PA)

Biotechnology · market cap $56M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-10-31 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

The catalyst path

2026-10-31 (est.)Phase 2 · Pooled allogeneic fecal microbiotherapyimp 7/10

Pipeline

Asset	Phase	Indication
MaaT013	Phase 3	Acute Graft Versus Host Disease in Intestine
Autologous Fecal Microbiota Transplantation	Phase 2	Leukemia, Myeloid, Acute
Pooled allogeneic fecal microbiotherapy	Phase 2	Transplant Complication
fecal microbiota transfer	Phase 2	Fecal Microbiota Transplantation

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for MAAT.PA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.